Source:

Press Release

January 25, 2022
1 min read
Save

Gene therapy platform for Stargardt macular degeneration receives IND clearance

Source:

Press Release

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The FDA has granted investigational new drug clearance to Nanoscope Therapeutics for a phase 2 trial investigating MCO-010 in patients with Stargardt macular degeneration, according to a press release.

“This is another important milestone for Nanoscope, giving us the opportunity of conducting a second clinical trial in the U.S. of our proprietary MCO gene therapy platform, designed to restore vision for patients suffering from retinal degenerative diseases,” Sulagna Bhattacharya, CEO of Nanoscope Therapeutics, said in the release.

MCO-010, a “multi-characteristic opsin ambient-light activatable optogenetic monotherapy,” is being evaluated in a phase 2b multicenter, randomized, sham-controlled, double-masked study in patients with retinitis pigmentosa, according to the release.

Nanoscope is planning to begin the phase 2 clinical trial in Stargardt macular degeneration in the first half of 2022.